Medical Research
(H30)
IRS Verified
DX Registered
990 on File
GLIOBLASTOMA FOUNDATION INC
Financial strength (30%)
88/100
Reliability (20%)
50/100
Effectiveness (25%)
85/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Mission Statement
To modify the current standard of care for glioblastoma by replacing radiation and chemotherapy with targeted small molecule therapies that prolong survival and increase quality of life.
Financial Overview — FY 2024
$2.1M
Total Revenue
$1.8M
Total Expenses
$3.2M
Net Assets
21
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
86.3%
Fundraising Efficiency
9.8%
Operating Reserve
20.72x
Liability-to-Asset
13.6%
Revenue Diversification
95.6%
Executive Compensation
$343K
Compared with Peers
FY 2024
Compared with 332 similar organizations
(United States, Medical Research, $1M–$10M in expenses), FY 2024.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
86.3% | 83.0% |
P10P90
|
Above median |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
13.0% | 10.7% |
P10P90
|
Below median |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
0.8% | 2.0% |
P10P90
|
Above median |
|
Fundraising efficiency
Fundraising expenses / gross fundraising income
· lower is better
|
9.8% | 97.3% |
P10P90
|
Top quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
20.7 mo | 12.8 mo |
P10P90
|
Above median |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
13.6% | 10.1% |
P10P90
|
Below median |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
95.6% | 90.7% |
P10P90
|
Below median |
|
Revenue growth
Year over year revenue growth
|
20.9% | 12.5% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
29.9% | 11.1% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
10.8% | 2.9% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2024 | $2.1M | $1.8M | $3.2M | 86.3% | 21 |
| 2023 | $1.7M | $1.4M | $2.5M | 86.2% | 14 |
| 2022 | $1.5M | $854K | $1.8M | 70.9% | 5 |
| 2021 | $1.3M | $703K | $1.5M | 73.2% | 5 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.